title: What level of hepatitis B antibody is protective?
abstract: This study assessed the level of vaccine-induced hepatitis B surface antibody that is protective against hepatitis B infection and carriage in The Gambia. Sera from 700 of a cohort of 1041 children vaccinated against hepatitis B in infancy were serially tested for markers of hepatitis B until age 7 years. No absolute level of protection against infection was found, but all children who attained a peak antibody response to vaccination of >=10 IU/L were protected against carriage of hepatitis B surface antigen. Two-thirds of 45 infected children experienced brief infection (determined by loss of core antibody). This transient infection was likely related to surface antibody level. The data support the use of the peak antibody response as the best indicator of protection against carriage and suggest that most infections after vaccination are short-lived.
authors.affiliation: Gambia Hepatitis Intervention Study, International Agency for Research on Cancer and Medical Research Council Laboratories, Fajara, The Gambia.
authors.forename: A D
authors.initials: AD
authors.lastname: Jack
authors.forename: A J
authors.initials: AJ
authors.lastname: Hall
authors.forename: N
authors.initials: N
authors.lastname: Maine
authors.forename: M
authors.initials: M
authors.lastname: Mendy
authors.forename: H C
authors.initials: HC
authors.lastname: Whittle
mesh_terms: D000915:Antibody Affinity; D015415:Biomarkers / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005500:Follow-Up Studies; D005714:Gambia; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans; D007223:Infant; D014758:Viral Core Proteins / Q000276:immunology
chemical_list: D015415:Biomarkers; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D014758:Viral Core Proteins